Novel mGluR5 Modulator Effects on Alcohol Drinking and MRI Outcomes
Status:
Not yet recruiting
Trial end date:
2026-04-22
Target enrollment:
Participant gender:
Summary
This study evaluates the effects of the medication GET73 among non-treatment-seeking
individuals who regularly drink alcohol. Participants in the study will take GET73 or placebo
for an 8-day study. There are 4 study visits including 2 MRI scans.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Medical University of South Carolina
Collaborators:
National Institute on Alcohol Abuse and Alcoholism (NIAAA) National Institutes of Health (NIH)